Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Marisa Valentinetti"'
Autor:
Sattva S. Neelapu, Judy Smith, M. Alma Rodriguez, Michelle A. Fanale, Anas Younes, Andre Goy, L. Jeffrey Medeiros, Peggy Ford, Felipe Samaniego, Barbara Pro, Lei Feng, Frederick B. Hagemeister, Robert Z. Orlowski, Nathan Fowler, Larry W. Kwak, Jorge E. Romaguera, Adam Naig, Marisa Valentinetti, Luis Fayad, Michael Wang, Yasuhiro Oki, Hagop M. Kantarjian, Kimberly Hartig, Peter McLaughlin
Publikováno v:
Cancer. 124:2561-2569
Background Although the outcomes of patients with mantle cell lymphoma (MCL) have improved, there is still no cure. Bortezomib has a 33% response rate in relapsed/refractory MCL and has shown additive and/or synergistic effects in preclinical trials
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe5c2f9da58543202c90c30fc10ba6fe
https://doi.org/10.1002/cncr.31361
https://doi.org/10.1002/cncr.31361
Autor:
Pritish K. Bhattacharyya, Christina Howlett, Jakub Svoboda, Mary Mrkulic, Kelly Azzollini, Gabriella Gadaleta, Tatyana Feldman, Coleen Bejot, Lauren-Nicole Pascual, Kara Yannotti, Sabrina Kdiry, Andre Goy, Joshua Zenreich, Stephen J. Schuster, Kar Fai Chow, Lauren E. Strelec, David L. Porter, Kenneth A. Foon, Anthony R. Mato, Marisa Valentinetti
Publikováno v:
American Journal of Hematology. 90:487-492
Fludarabine, cyclophosphamide, and rituximab (FCR) remains the standard of care for fit chronic lymphocytic leukemia (CLL) patients requiring first therapy. However, side effects can be significant, and patients with poor risk features have inferior
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4269d3b23da6b4f7201ea7aa598a0d71
https://doi.org/10.1002/ajh.23983
https://doi.org/10.1002/ajh.23983
Autor:
Anthony R, Mato, Kenneth A, Foon, Tatyana, Feldman, Stephen J, Schuster, Jakub, Svoboda, Kar Fai, Chow, Marisa, Valentinetti, Mary, Mrkulic, Kelly, Azzollini, Gabriella, Gadaleta, Pritish K, Bhattacharyya, Joshua, Zenreich, Lauren-Nicole, Pascual, Kara, Yannotti, Sabrina, Kdiry, Christina, Howlett, Lauren, Strelec, David, Porter, Coleen, Bejot, André, Goy
Publikováno v:
American journal of hematology. 90(6)
Fludarabine, cyclophosphamide, and rituximab (FCR) remains the standard of care for fit chronic lymphocytic leukemia (CLL) patients requiring first therapy. However, side effects can be significant, and patients with poor risk features have inferior
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5d373c7ff714df43eb577ac494ca76e1
https://pubmed.ncbi.nlm.nih.gov/25691474
https://pubmed.ncbi.nlm.nih.gov/25691474
Autor:
Eric Hansen, Alan P Skarbnik, Tatyana Feldman, Marisa Valentinetti, Kelly Choi, Andre Goy, Judy L. Smith, Srikesh Arunajadai, Tommy Wu, Lori A. Leslie, Ewelina Protomastro
Publikováno v:
Journal of Clinical Oncology. 35:e19030-e19030
e19030 Background: The peripheral blood absolute lymphocyte-to-monocyte ratio (ALC/AMC) is prognostic of overall survival (OS) in Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma, and several solid tumors. Lymphocyte and monocytes have been suggested
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::53609a964dd97e79ff916dab3dabe1ba
https://doi.org/10.1200/jco.2017.35.15_suppl.e19030
https://doi.org/10.1200/jco.2017.35.15_suppl.e19030
Autor:
Susan Stives, Andre Goy, Xiao Yang, Tatyana Feldman, Mary Timberg, Kara Yannotti, Kar F. Chow, Gabriella Gadaleta, Sabrina Kdiry, Pritish K. Bhattacharyya, Andrew L. Pecora, Coleen Bejot, Michele L. Donato, Scott D. Rowley, Judith Smith, Marisa Valentinetti, Anne W. Beaven, Ewelina Protomastro, Anthony R. Mato, Carolanne Carini
Publikováno v:
British Journal of Haematology
Relapsed/refractory diffuse large B-cell lymphoma (DLBCL) is associated with a poor prognosis. Outcomes are particularly poor following immunochemotherapy failure or relapse within 12 months of induction. We conducted a Phase I/II trial of lenalidomi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d63c4d5b377dcc0dafa20dbf290d6a6b
https://pubmed.ncbi.nlm.nih.gov/24661044
https://pubmed.ncbi.nlm.nih.gov/24661044
Autor:
Mona Sadekh, Alan P Skarbnik, Marisa Valentinetti, Andre Goy, Chad Glisch, Xiao Yang, Anthony R. Mato, Larysa Jessica Gromko, Tatyana Feldman, Lina Starovoitova, Susan Stives, Ewelina Protomastro, Mary Timberg, Pritish K. Bhattacharyya, Kar Fai Chow, Benjamin Schoener
Publikováno v:
Blood. 124:1307-1307
Background: Rituximab has increased the CR rate, improved both PFS and OS and changed the pattern of relapse of DLBCL pts treated with R-CHOP (leading to a > 50% cure). In contrast to the pre rituximab era, the majority of failures occur early (80% o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::be9e09380a74636fdcd0a98b522349b8
https://doi.org/10.1182/blood.v124.21.1307.1307
https://doi.org/10.1182/blood.v124.21.1307.1307
Autor:
Sabrina Kdiry, Christina Howlett, Joshua Zenreich, Kenneth A. Foon, Lauren-Nicole Pascual, Stephen J. Schuster, Anthony R. Mato, Marisa Valentinetti, Andre Goy, David L. Porter, Mary Morin, Gabriella Magarelli, Tatyana Feldman, Kar Fai Chow, Pritish K. Bhattacharyya, Jakub Svoboda, Kelly Azzollini, Kara Yanotti
Publikováno v:
Blood. 124:4678-4678
Introduction: Fludarabine, cyclophosphamide, rituximab (FCR) remains the standard of care for the treatment of newly diagnosed, fit CLL pts requiring therapy. However, the FCR side effects profile is non-trivial and CLL pts with poor risk features ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6d946134200474afb285e32a8b4284fa
https://doi.org/10.1182/blood.v124.21.4678.4678
https://doi.org/10.1182/blood.v124.21.4678.4678
Autor:
Marisa Valentinetti, Anthony R. Mato, Carolanne Carini, Judith Smith, Andre Goy, Joshua R. Richter, Michele L. Donato, Stuart L. Goldberg, David S. Siegel, Ewelina Protomastro, Susan Stives, Andrew L. Pecora, Tatyana Feldman, Gabriella Gadaleta, Coleen Bejot, Mary Timberg, David H. Vesole, Scott D. Rowley
Publikováno v:
Blood. 120:3710-3710
Abstract 3710 Background: Relapsed/refractory DLBCL has poor prognosis in the rituximab era. Pts who failed Rituximab-containing initial chemo regimen within 12 mo do particularly poorly. (ORR 46–51% vs. 83–88%, EFS 20% vs. 45% at three years). N
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c465fb7f45fa385d75d1412796d1ead0
https://doi.org/10.1182/blood.v120.21.3710.3710
https://doi.org/10.1182/blood.v120.21.3710.3710